Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

YM BioSciences Inc YMI



NYSEAM:YMI - Post by User

YM BioSciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by daydream1on Dec 06, 2010 2:02pm
579 Views
Post# 17807075

Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387

Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Great results.  Now if only YM could secure a deal with one of the major pharmaceutical Co. on distribution, YM would be off to the races.

Goodluck
D.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities